|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neoptolemos JP, Stocken DD, Friess H,
Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L,
Dervenis C, et al: A randomized trial of chemoradiotherapy and
chemotherapy after resection of pancreatic cancer. N Engl J Med.
350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oettle H, Neuhaus P, Hochhaus A, Hartmann
JT, Gellert K, Ridwelski K, Niedergethmann M, Zülke C, Fahlke J,
Arning MB, et al: Adjuvant chemotherapy with gemcitabine and
long-term outcomes among patients with resected pancreatic cancer:
The CONKO-001 randomized trial. JAMA. 310:1473–1481. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eguchi H, Nagano H, Tanemura M, Takeda Y,
Marubashi S, Kobayashi S, Kawamoto K, Wada H, Hama N, Akita H, et
al: Preoperative chemoradiotherapy, surgery and adjuvant therapy
for resectable pancreatic cancer. Hepatogastroenterology.
60:904–911. 2013.PubMed/NCBI
|
|
5
|
Ohigashi H, Ishikawa O, Eguchi H,
Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H,
Tomita Y and Nishiyama K: Feasibility and efficacy of combination
therapy with preoperative full-dose gemcitabine, concurrent
three-dimensional conformal radiation, surgery and postoperative
liver perfusion chemotherapy for T3-pancreatic cancer. Ann Surg.
250:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans DB, Varadhachary GR, Crane CH, Sun
CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA,
et al: Preoperative gemcitabine-based chemoradiation for patients
with resectable adenocarcinoma of the pancreatic head. J Clin
Oncol. 26:3496–3502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takahashi H, Ohigashi H, Gotoh K,
Marubashi S, Yamada T, Murata M, Ioka T, Uehara H, Yano M and
Ishikawa O: Preoperative gemcitabine-based chemoradiation therapy
for resectable and borderline resectable pancreatic cancer. Ann
Surg. 258:1040–1050. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Matsuda T, Taniguchi F, Minato H, Nomura
H, Tsuda T and Aikawa I: Successful resection of advanced
pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy:
Report of a case. Surg Today. 36:754–757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fortner JG, Klimstra DS, Senie RT and
Maclean BJ: Tumor size is the primary prognosticator for pancreatic
cancer after regional pancreatectomy. Ann Surg. 223:147–153. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Griffanti-Bartoli F, Arnone GB, Ceppa P,
Ravera G, Carrabetta S and Civalleri D: Malignant tumors in the
head of the pancreas and the periampullary region. Diagnostic and
prognostic aspects. Anticancer Res. 14:657–666. 1994.PubMed/NCBI
|
|
11
|
Raut CP, Tseng JF, Sun CC, Wang H, Wolff
RA, Crane CH, Hwang R, Vauthey JN, Abdalla EK, Lee JE, et al:
Impact of resection status on pattern of failure and survival after
pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg.
246:52–60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ozaki H, Hiraoka T, Mizumoto R, Matsuno S,
Matsumoto Y, Nakayama T, Tsunoda T, Suzuki T, Monden M, Saitoh Y,
et al: The prognostic significance of lymph node metastasis and
intrapancreatic perineural invasion in pancreatic cancer after
curative resection. Surg Today. 29:16–22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dvorak HF: Tumors: Wounds that do not
heal. Similarities between tumor stroma generation and wound
healing. N Engl J Med. 315:1650–1659. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mantovani A, Allavena P, Sica A and
Balkwill F: Cancer-related inflammation. Nature. 454:436–444. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bambury RM, Teo MY, Power DG, Yusuf A,
Murray S, Battley JE, Drake C, O'Dea P, Bermingham N, Keohane C, et
al: The association of pre-treatment neutrophil to lymphocyte ratio
with overall survival in patients with glioblastoma multiforme. J
Neurooncol. 114:149–154. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fox P, Hudson M, Brown C, Lord S, Gebski
V, De Souza P and Lee CK: Markers of systemic inflammation predict
survival in patients with advanced renal cell cancer. Br J Cancer.
109:147–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shimazaki J, Goto Y, Nishida K and Tabuchi
T, Motohashi G, Ubukata H and Tabuchi T: In patients with
colorectal cancer, preoperative serum interleukin-6 level and
granulocyte/lymphocyte ratio are clinically relevant biomarkers of
long-term cancer progression. Oncology. 84:356–361. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC: An
inflammation-based prognostic score (mGPS) predicts cancer survival
independent of tumour site: A Glasgow Inflammation Outcome Study.
Br J Cancer. 104:726–734. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
23
|
Garcea G, Ladwa N, Neal CP, Metcalfe MS,
Dennison AR and Berry DP: Preoperative neutrophil-to-lymphocyte
ratio (NLR) is associated with reduced disease-free survival
following curative resection of pancreatic adenocarcinoma. World J
Surg. 35:868–872. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Smith RA, Bosonnet L, Raraty M, Sutton R,
Neoptolemos JP, Campbell F and Ghaneh P: Preoperative
platelet-lymphocyte ratio is an independent significant prognostic
marker in resected pancreatic ductal adenocarcinoma. Am J Surg.
197:466–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumors (7th). Oxford:
Wiley-Blackwell. 2010.
|
|
26
|
Buzby GP, Mullen JL, Matthews DC, Hobbs CL
and Rosato EF: Prognostic nutritional index in gastrointestinal
surgery. Am J Surg. 139:160–167. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eguchi H, Nagano H, Kobayashi S, Kawamoto
K, Wada H, Hama N, Tomimaru Y, Akita H, Sakai D, Satoh T, et al: A
phase I trial of combination therapy using gemcitabine and S-1
concurrent with full-dose radiation for resectable pancreatic
cancer. Cancer Chemother Pharmacol. 73:309–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Evans DB, Rich TA, Byrd DR, Cleary KR,
Connelly JH, Levin B, Charnsangavej C, Fenoglio CJ and Ames FC:
Preoperative chemoradiation and pancreaticoduodenectomy for
adenocarcinoma of the pancreas. Arch Surg. 127:1335–1339. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kishi Y, Kopetz S, Chun YS, Palavecino M,
Abdalla EK and Vauthey JN: Blood neutrophil-to-lymphocyte ratio
predicts survival in patients with colorectal liver metastases
treated with systemic chemotherapy. Ann Surg Oncol. 16:614–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang N, Deng JY, Liu Y, Ke B, Liu HG and
Liang H: The role of preoperative neutrophil-lymphocyte and
platelet-lymphocyte ratio in patients after radical resection for
gastric cancer. Biomarkers. 19:444–451. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cho H, Hur HW, Kim SW, Kim SH, Kim JH, Kim
YT and Lee K: Pre-treatment neutrophil to lymphocyte ratio is
elevated in epithelial ovarian cancer and predicts survival after
treatment. Cancer Immunol Immunother. 58:15–23. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gomez D, Morris-Stiff G, Toogood GJ, Lodge
JP and Prasad KR: Impact of systemic inflammation on outcome
following resection for intrahepatic cholangiocarcinoma. J Surg
Oncol. 97:513–518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gomez D, Farid S, Malik HZ, Young AL,
Toogood GJ, Lodge JP and Prasad KR: Preoperative
neutrophil-to-lymphocyte ratio as a prognostic predictor after
curative resection for hepatocellular carcinoma. World J Surg.
32:1757–1762. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stotz M, Gerger A, Eisner F, Szkandera J,
Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewies FS, Lackner
C, et al: Increased neutrophil-lymphocyte ratio is a poor
prognostic factor in patients with primary operable and inoperable
pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sato H, Tsubosa Y and Kawano T:
Correlation between the pretherapeutic neutrophil to lymphocyte
ratio and the pathologic response to neoadjuvant chemotherapy in
patients with advanced esophageal cancer. World J Surg. 36:617–622.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dou X, Wang RB, Yan HJ, Jiang SM, Meng XJ,
Zhu KL, Xu XQ and Mu DB: Circulating lymphocytes as predictors of
sensitivity to preoperative chemoradiotherapy in rectal cancer
cases. Asian Pac J Cancer Prev. 14:3881–3885. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Müller I, Munder M, Kropf P and Hänsch GM:
Polymorphonuclear neutrophils and T lymphocytes: Strange bedfellows
or brothers in arms? Trends Immunol. 30:522–530. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rodriguez PC, Ernstoff MS, Hernandez C,
Atkins M, Zabaleta J, Sierra R and Ochoa AC: Arginase I-producing
myeloid-derived suppressor cells in renal cell carcinoma are a
subpopulation of activated granulocytes. Cancer Res. 69:1553–1560.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shamamian P, Schwartz JD, Pocock BJ, Monea
S, Whiting D, Marcus SG and Mignatti P: Activation of progelatinase
A (MMP-2) by neutrophil elastase, cathepsin G and proteinase-3: A
role for inflammatory cells in tumor invasion and angiogenesis. J
Cell Physiol. 189:197–206. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Scapini P, Nesi L, Morini M, Tanghetti E,
Belleri M, Noonan D, Presta M, Albini A and Cassatella MA:
Generation of biologically active angiostatin kringle 1–3 by
activated human neutrophils. J Immunol. 168:5798–5804. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Di Carlo E, Forni G and Musiani P:
Neutrophils in the antitumoral immune response. Chem Immunol
Allergy. 83:182–203. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density and location of immune cells
within human colorectal tumors predict clinical outcome. Science.
313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morris M, Platell C and Iacopetta B:
Tumor-infiltrating lymphocytes and perforation in colon cancer
predict positive response to 5-fluorouracil chemotherapy. Clin
Cancer Res. 14:1413–1417. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Galon J, Pagès F, Marincola FM, Thurin M,
Trinchieri G, Fox BA, Gajewski TF and Ascierto PA: The immune score
as a new possible approach for the classification of cancer. J
Transl Med. 10:12012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Motoi F, Unno M, Takahashi H, et al:
Influence of preoperative anti-cancer therapy on resectability and
perioperative outcomes in patients with pancreatic cancer: Project
study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery.
J Hepatobiliary Pancreat Sci. 21:148–158. 2014. View Article : Google Scholar : PubMed/NCBI
|
